Jobs
-
Mylan gets Pfizer’s respiratory delivery platform, acquires global rights to generic Diskus products
US generics company Mylan Inc. has obtained worldwide rights to develop, manufacture and commercialize Pfizer’s generic equivalent to GlaxoSmithKline’s Advair Diskus and Seretide Diskus products for asthma and COPD using Pfizer’s proprietary dry powder inhalation technology.… Read more . . .
-
Within the last week, Discovery Laboratories has announced that its aerosolized KL4 surfactant has received orphan drug designation from the EU for the treatment of cystic fibrosis, and it has presented data on a new… Read more . . .
-
Sunovion is presenting results from a 26-week double-blind, randomized Phase 3 study of ciclesonide HFA nasal aerosol involving more than 1,100 patients with perennial allergic rhinitis (PAR) that showed statistically significant improvement in nasal symptoms… Read more . . .
-
The 2011 Drug Delivery to the Lungs (DDL) Conference, which takes place December 7-9 in Edinburgh, UK, will highlight a particularly strong field of scientific presentations from both established industry experts and up-and-coming young researchers,… Read more . . .
-
CRO Catalent Pharma Solutions has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), a consortium of companies involved in the development, manufacture, and marketing of OINDPs, whose mission is “to advance scientifically… Read more . . .
-
US Senator Jim DeMint, a Republican from South Carolina, failed to persuade the US Senate to prohibit the use of tax dollars for enforcement of the FDA ban on the CFC-propelled OTC epinephrine inhaler Primatene… Read more . . .
-
OINDP researchers with a particular interest in powder flow and rheology should take note that poster abstract submission and early registration for Powder Flow 2011 end on November 4. The meeting is organized by the… Read more . . .
-
Lightlake Therapeutics has provided additional details of recently announced Phase 2 trials of its naloxone nasal spray for binge eating disorder and for bulimia nervosa. Binge eating disorder trials have begun in Helsinki, with 138… Read more . . .
-
The 2011 annual meeting of the American Association of Pharmaceutical Scientists in Washington, DC, which took place from October 23-27, included presentations of research related to OINDPs in several formats: a pre-workshop on “Developing Pharmaceutical… Read more . . .
-
Swedish pharmaceutical company Meda has submitted a marketing authorization application for Dymista azelastine hydrochloride/fluticasone propionate nasal spray for the treatment of moderate-to-severe allergic rhinitis and rhinoconjuctivitisto the EMA. An NDA for Dymista was submitted to… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.